n.a. (MAXY)

0.00
NASDAQ
Prev Close 0.00
Day Low/High 0.00 / 0.00
52 Wk Low/High 0.00 / 0.00
Exchange NASDAQ
Div & Yield N.A. (N.A)

Latest News

Maxygen Announces Approval Of Dissolution By Shareholders

Maxygen Announces Approval Of Dissolution By Shareholders

Maxygen, Inc. (Nasdaq: MAXY), today announced that at the company’s annual meeting, held earlier today, the shareholders of Maxygen voted to approve the liquidation and dissolution of the company.

Maxygen Reports Second Quarter 2013 Financial Results

Maxygen Reports Second Quarter 2013 Financial Results

Maxygen, Inc. (Nasdaq: MAXY), a biopharmaceutical company, today announced financial results for the quarter ended June 30, 2013.

Maxygen Reports Fourth Quarter And Year End 2012 Financial Results

Maxygen Reports Fourth Quarter And Year End 2012 Financial Results

Maxygen, Inc. (Nasdaq: MAXY), a biopharmaceutical company, today announced financial and business results for the quarter and year ended December 31, 2012.

Maxygen Announces Tax Treatment Of 2012 Cash Distribution

Maxygen Announces Tax Treatment Of 2012 Cash Distribution

Maxygen, Inc. (Nasdaq: MAXY), a biotechnology company, today announced that its distribution of cash in September 2012 primarily will be classified as a return of capital to its stockholders for U.

Maxygen Announces Third Quarter 2012 Financial Results

Maxygen Announces Third Quarter 2012 Financial Results

Maxygen, Inc. (Nasdaq:MAXY), a biotechnology company, today announced financial and business results for the quarter ended September 30, 2012.

Maxygen Inc. Stock Downgraded (MAXY)

Maxygen Inc. Stock Downgraded (MAXY)

Maxygen (Nasdaq:MAXY) has been downgraded by TheStreet Ratings from from a buy to hold.

Maxygen Inc. Stock Upgraded (MAXY)

Maxygen Inc. Stock Upgraded (MAXY)

Maxygen (Nasdaq:MAXY) has been upgraded by TheStreet Ratings from a hold to buy.

Maxygen Announces Second Quarter 2012 Financial Results And Business Update

Maxygen Announces Second Quarter 2012 Financial Results And Business Update

Maxygen, Inc. (Nasdaq: MAXY), a biotechnology company, today announced financial and business results for the quarter ended June 30, 2012.

Maxygen Inc. Stock Upgraded (MAXY)

Maxygen Inc. Stock Upgraded (MAXY)

Maxygen (Nasdaq:MAXY) has been upgraded by TheStreet Ratings from a sell to hold.

Maxygen Reports First Quarter 2012 Financial Results

Maxygen Reports First Quarter 2012 Financial Results

Maxygen, Inc. (Nasdaq:MAXY), a biopharmaceutical company, today announced financial and business results for the quarter ended March 31, 2012.

Maxygen Inc. Stock Downgraded (MAXY)

Maxygen Inc. Stock Downgraded (MAXY)

Maxygen (Nasdaq:MAXY) has been downgraded by TheStreet Ratings from from a hold to sell.

Maxygen Reports Fourth Quarter And Year End 2011 Financial Results

Maxygen Reports Fourth Quarter And Year End 2011 Financial Results

Maxygen, Inc. (Nasdaq:MAXY), a biopharmaceutical company, today announced financial and business results for the quarter and year ended December 31, 2011.

Maxygen Announces $10 Million Stock Repurchase Program

Maxygen Announces $10 Million Stock Repurchase Program

Maxygen, Inc. (Nasdaq: MAXY), a biotechnology company, today announced that its Board of Directors has approved a new stock repurchase program under which the company may purchase up to $10.

Maxygen Announces BARDA Decision Not To Award Contract For Development Of MAXY-G34 For Acute Radiation Syndrome

Maxygen, Inc. (Nasdaq:MAXY) today announced that it has been advised by the Biomedical Advanced Research and Development Authority (BARDA) that Maxygen’s proposal for the development of its MAXY-G34 product candidate ...

Maxygen Reports Third Quarter 2011 Financial Results

Maxygen, Inc. (Nasdaq:MAXY), a biotechnology company, today announced financial and business results for the quarter ended September 30, 2011.

Maxygen Announces Final Rejection Of All Claims Of Amgen ‘804 Patent In Inter Partes Reexamination Proceeding

Maxygen, Inc. (Nasdaq:MAXY), a biotechnology company, today announced that the United States Patent and Trademark Office (PTO) has issued a Right of Appeal Notice in the inter partes reexamination proceeding for ...

Maxygen Announces $10 Million Increase In Stock Repurchase Program

Maxygen, Inc. (Nasdaq:MAXY), a biotechnology company, today announced that its Board of Directors has approved an increase to the company’s current stock repurchase program from $10.

Maxygen Reports Second Quarter 2011 Financial Results

Maxygen, Inc. (Nasdaq: MAXY), a biotechnology company, today announced financial and business results for the quarter ended June 30, 2011.

Maxygen Announces $10 Million Stock Repurchase Program

Maxygen, Inc. (Nasdaq:MAXY), a biotechnology company, today announced a stock repurchase program under which the company may purchase up to $10.

Astellas And Maxygen Announce Completion Of Acquisition Of Perseid By Astellas

Astellas Pharma Inc. (“Astellas”);(TOKYO:4503) and Maxygen, Inc.

Maxygen Reports First Quarter 2011 Financial Results

Maxygen, Inc. (Nasdaq:MAXY), a biopharmaceutical company focused on developing improved versions of protein drugs through both internal development and external collaborations and other arrangements, today announced...

Maxygen Submits Proposal To BARDA For Development Of MAXY-G34 For Acute Radiation Syndrome

Maxygen, Inc. (Nasdaq:MAXY) today announced that it has submitted a proposal to the Biomedical Advanced Research and Development Authority (BARDA) for a multi-year, multi-million dollar contract for the development of...

Maxygen Stock Soars Higher (MAXY)

Shares of Maxygen (Nasdaq:MAXY) have taken a tremendous swing upward. The stock is trading at $5.30 as of 9:32 a.m. ET, 28.9% above Wednesday's closing price of $4.11. Volume is at 262,647, two times the daily average of 134,500.

Astellas Exercises Option To Purchase Maxygen’s Interest In Perseid

Maxygen, Inc. (Nasdaq:MAXY) today announced that Astellas Pharma Inc.

Maxygen Inc. Stock Upgraded (MAXY)

Maxygen (Nasdaq:MAXY) has been upgraded by TheStreet Ratings from a sell to hold.

Maxygen Reports Fourth Quarter And Year End 2010 Financial Results

Maxygen, Inc. (Nasdaq:MAXY), a biopharmaceutical company focused on developing improved versions of protein drugs through both internal development and external collaborations and other arrangements, today announced...

Maxygen Announces Tax Treatment Of 2010 Distributions

Maxygen, Inc. (Nasdaq:MAXY), a biotechnology company focused on the development of improved protein drugs, today announced that its distributions of Codexis, Inc.

Maxygen Announces Initiation Of Phase I Clinical Trial Under Perseid’s Collaboration With Astellas For CTLA4-Ig Program

Maxygen, Inc. (Nasdaq:MAXY), a biotechnology company focused on the development of improved protein drugs, today announced the initiation of a Phase I clinical study to evaluate a next-generation CTLA4-Ig therapeutic...